[Gene therapy of neurologic diseases. Experimental approaches and clinical perspectives].
So far, it has not been possible to treat many neurological conditions causally. However, in the past few years underlying genetic defects have been characterized for a substantial number of neurodegenerative disorders. Experimental methods have been developed that allow for efficient gene transfer into defined regions of the mammalian CNS. Such techniques can be applied to deliver genes into target cells of a recipient organism or to transfer genetically modified cells into defined regions of the CNS. Candidate genes for gene therapy are those encoding for neurotrophins and neurotransmitters for symptomatic therapy and, in the case of neurodegenerative disorders with localized gene defects, the wild-type allele as a causal treatment approach. In this review article, we describe some of the most widely used strategies for gene transfer to the CNS. We also report on the results obtained with animal models for human disease, and discuss both the chances and problems of gene therapy approaches in clinical medicine.
Isenmann
S
S
Neurologische Universitätsklinik, Tübingen.
Bähr
M
M
Dichgans
J
J
D000818:Animals; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009410:Nerve Degeneration / Q000235:genetics; D009414:Nerve Growth Factors / Q000235:genetics; D009422:Nervous System Diseases / Q000235:genetics* / Q000628:therapy; D018377:Neurotransmitter Agents / Q000235:genetics
D009414:Nerve Growth Factors; D018377:Neurotransmitter Agents